Life Science Investing Kymera Therapeutics Announces Late-Breaking Oral Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the European Academy of Dermatology & Venereology and European Respiratory Society Congresses
Life Science Investing Kymera Therapeutics Appoints Brian Adams as Chief Legal Officer and Corporate Secretary
